Port delivery system efficiently delivers drugs to retina in patients with wet AMD, study reports
November 15th 2021In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Mark Wieland, MD, noted that the Port Delivery System with ranibizumab provides drug delivery over an extended period.
Ocular surface tumors, though rare, often prove deadly
November 13th 2021In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall, BS, MS, pointed out that an epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.
Optic nerve pallor proves prevalent in ZIKA virus patients, study finds
November 13th 2021During a presentation at the American Academy of Ophthalmology 2021 annual meeting, Denise Freitas, MD, reported that the ocular findings in infants with congenital Zika virus syndrome were similar among the affected infants and occurred frequently. The most prevalent of the findings was optic nerve pallor.
Bimatoprost implant reduces IOP for 2 years or more, study finds
November 12th 2021Felipe Medeiros, MD, in a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.
Increase in corneal haze after corneal crosslinking connected with mitomycin C
November 12th 2021Shady Awwad, MD, in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.
Brolucizumab deemed noninferior to aflibercept for DME treatment, fewer injections required
November 12th 2021During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dilsher Dhoot, MD, reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular edema.